Biopharmaceutical Drug Delivery - - BioPharm International

ADVERTISEMENT

Biopharmaceutical Drug Delivery


BioPharm International


Controlled delivery. Both the drug's duration (for sustained delivery) and its site (targeted delivery) of action and bioavailability can be controlled. Targeted delivery has been practiced for some time using monoclonal antibodies and surgical implantation, among other methods (see the "Blood-Brain Barrier" box on Page 22). Sustained delivery is gaining much interest in the biopharmaceutical arena.

According to Nandini Katre of SkyePharma, "The major challenges in formulating therapeutic proteins and peptides for sustained delivery are as follows: maintaining the structural integrity of the therapeutic molecule to preserve its bioactivity and stability; obtaining high loading in the delivery vehicle to ensure sufficient bioavailability for the duration of therapy; providing sustained therapeutic levels for the desired duration without a 'burst' effect, controlling the duration of drug release to accommodate a range of dosing regimens that match therapeutic needs; and providing in vivo biological effects that can be sustained over the required period of time."

For sustained delivery, a depot (reservoir) of drug is created in the body (at the injection site, for example), from which the drug is released over a specified time. Biodegradable polymers open the possibility of implants that deliver a drug over days or months. Like any other method, sustained delivery presents certain challenges. In time, a protein may interact with its surrounding matrix, or the implant could be attacked by the immune system. If proteins stick (adsorb) to the delivery matrix, they may not be released at all. Even before implantation, creation of a delivery matrix often involves steps that can harm proteins. Four methods of creating a delivery matrix for sustained delivery can be used with biopharmaceuticals: emulsification, coacervation, extrusion, and polymerization.

Emulsification. When the drug is water-soluble but the delivery matrix is not, they are dissolved into two different media and then mixed to create a water-in-oil emulsion. Usually, for better protein distribution, that emulsion is dispersed and mixed with a second aqueous solution to create a water-in-oil-in-water emulsion. The interfaces created by the droplets can denature proteins, especially when a series of emulsions are used to create the delivery matrix. Additionally, energy is required to combine the two (mechanical or ultrasonic mixing), which also can denature proteins.

Coacervation. In coacervation, formulators add a competing molecule that is more soluble to a solution of the protein in liquid. The resulting chemical reactions create microspheres of the drug. This method is gentler than emulsification, but some loss of bioactivity can happen through pH changes and chemical reactions.

Extrusion. A solution or particulate formulation is forced through holes to form microdroplets. High shear forces may damage proteins. Combining this technique with lyophilization may be a better choice because the cold, dry form is more stable, and the protein receives some protection from shear forces.

Polymerization. Hydrogels, polymers that swell when they come into contact with water or an aqueous solvent, are mixed with the drug. Electromagnetic radiation forces chemical reactions that create a gel matrix to carry the drug.



Inhaled Biopharmaceuticals Offering an almost direct line to the circulatory system, alveoli in the lungs would be a good place to deliver proteins. However, because the lungs are a pathway for infections, the body's defense mechanisms make the alveoli hard to reach. Pulmonary delivery of polypeptides requires a device such as a nebulizer that makes an aerosol of the formulation (a liquid or a lyophilized powder) for inhalation. Only very tiny particles can reach far enough into the lungs for efficient drug delivery. The portion of the particle size spectrum generally considered able to penetrate farthest and deposit well into the lungs (<2-3 m) is called the fine particle fraction (FPF). For biopharmaceutical drugs, a large portion of the device output should be 1-6 m. Particle size distribution and weight determine how far into the progressively smaller lung pathways the drug will go. Heavier particles are deposited sooner, sometimes just at the back of the throat. If swallowed, the drug is wasted (see "The Oral Route" on Page 29).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health
April 22, 2014
Novartis and GSK Trade Assets
April 22, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here